


Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE) M. Ueno¹, C. Morizane², M. Ikeda³ M. Ozaka⁴, F. Nagashima⁵, T. Kataoka⁶, J. Mizusawa⁷, A. Ohba², S. Kobayashi¹, H. Imaoka², A. Kasuga⁴, N. Okano⁵, Y. Nagasaka⁸, K. Kurishita⁸, S. Tomatsuri⁸, M. Sasaki³, T. Shibata⁷, K. Nakamura⁶, J. Furuse^{1,5}, T. Okusaka²

1 Department of Gastroenterology, Kanagawa Cancer Center, 2 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 3 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 7 Japan Clinical Oncology Group Data Center/National Cancer Center Hospital, 8 Clinical Research Support Office, National Cancer Center Hospital

4 Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 5 Department of Medical Oncology Group Operations Office/Clinical Research Support Office, National Cancer Center Hospital,

Background	Results							
 Although gemcitabine (GEM) combination chemotherapies have improved the survival of advanced biliary tract cancer (BTC) patients (pts), high unmet medical needs remain for the treatment of BTC. Lenvatinive monotherapy have shown modest efficacy in advanced BTC. Immune checkpoint inhibitors have shown limited efficacy in monotherapy for advanced BTC. Recently, combinations of them with other therapies have shown remarkable efficacy in multiple cancer types. This study aimed to assess the efficacy and safety of nivolumab plus lenvatinib in second-line treatment for advanced BTC. 		 Between Aug and Oct 2019, 6 pts were enrolled in phase I part, and until Nov 2020, 32 patients were totally enrolled in phase I+II part, from 5 centers. The recommended dose of lenvatinib was determined to be 20 mg in the 6 pts in phase I with one AE corresponding toxicity evaluation criteria of myocarditis. The trial was completed without a first-line expansion cohort because the efficacy in the phase II part was limited. 						
Methods				n (%)				
 The study included pts receiving second- aged <u>></u> 20 years, ECOG Performance state with measurable lesion. 	Median age, years [range] Sex	Male Female	63 [44-78] 23 (71.9) 9 (28.1)					
 Nivolumab (240 mg) was administered biweekly. Phase I was performed to determine the recommended phase II dose of lenvatinib (from 20 mg to 14 mg, daily). The primary endpoint in phase I is proportion of adverse events corresponding toxicity evaluation criteria. In phase II, the primary endpoint was the objective response rate (ORR). Secondary endpoints were disease control rate (DCR), progression-free 		ECOG PS	0 1	23 (71.9) 9 (28.1)				
		Primary tumor site	Gallbladder Extrahepatic bile duct Intrahepatic bile duct Ampullary	7 (21.9) 5 (15.6) 15 (46.9) 5 (15.6)				
 survival (PFS), overall survival (OS), and The tumor response was evaluated in according blinded independent central review. 	Extent of disease	Unresectable Recurrent	25 (78.1) 7 (21.9)					
Study design	Prior chemotherapy (First line)	GEM + CDDP GEM + CDDP + S-1	23 (71.9) 9 (28.1)					
Phase I (n=6) <u>Determine the recommended dose of lenvatinib</u> Lenvatinib initial dose: 20 mg or 14mg /daily Nivolumab fixed dose: 240 mg/day every 2 weeks Proportion of adverse events (AEs)	Phase II (n=32) Evaluation of efficacy and safety Lenvatinib 20 mg/day, daily Nivolumab 240 mg/day every 2 weeks Planned sample size is 32 including 6 pts enrolled in phase I part. CR or PR is observed	Microsatellite instability status (MSI status)	Stable High Unknown	27 (84.4) 0 (0.0) 5 (15.6)				
		Biliary drainage	Presence Absence	14 (43.8) 18 (56.3)				
corresponding toxicity evaluation criteria * observed in 0-2 pts: move to Phase II		Usage of antibiotics**	Yes No	9 (28.1) 23 (71.9)				
observed in 3-6 pts: add 6 pts to 1 level lower lenvatinib dose		** within 1 month before starting protocol treatment						
Expansion cohort (n=15) Table 2. Overall response (n=32)								
First-line treatment for BTC	RECIST 1.1	n (%)						
 * Toxicity evaluation criteria: ✓ Hematological toxicities: febrile-neutropenia, Grade 4 neutropenia for 7 days, Grade 4 platelet count decreased, Grade 3 platelet count decreased for 7 days or with bleeding, Grade 4 anemia ✓ Non-hematological toxicities: Grade 4 AEs, Grade 3 gastrointestinal perforation, Thromboembolic event, Uveitis, Pneumonitis, Bronchospasm, Allergic reaction, Infusion related reaction, Wound dehiscence needed treatment, Grade 3 AEs for 3 days after proper treatment, Grade 2 Uveitis, eye 		Complete response	0 (0.0)					
		Partial response	3 (9.4)					
		Stable disease	14 (43.8)					
pain, blurred vision treated locally and not improved to systemically, Adverse reactions requiring lenvatinib dis	Progressive disease	14 (43.8)						
 weeks The planned sample size was 32 pts in phase I+II, which provided 80% 		Not evaluated	1 (3.1)					
power for the primary endpoint with a one-sided alpha error of 5%, threshold		ORR [90% CI]	3 (9.4) [2.6-22.5]					
 ORR of 10% and expected ORR of 30%. If efficacy was expected in phase II, we p 	DCR [95% CI]	17 (53.1) [34.7-70.9]						
expansion cohort.		CI: confide	nce interval					

expansion cohort.






Table 1 Treatment-emergent adverse events (n=32)

able 4. Treatment-emergent ad	Any grade	Grade 3/4	CTCAE ver. 5.0	Any grade n (%)	G n
	n (%)	n (%)	Rash	9 (28.1)	1
	25 (78.1)	19 (59.4)	Hypothyroidism	7 (21.9)	0
Proteinuria	20 (62.5)	2 (6.3)	Malaise	6 (18.8)	1
Anorexia	17 (53.1)	2 (6.3)			
Platelet count decreased	16 (50.0)	3 (9.4)	Fever	4 (12.5)	0
Hoarseness	14 (43.8)	0	Anorexia	4 (12.5)	0
Biliary tract infection	13 (40.6)	12 (37.5)	Diarrhea	3 (9.4)	1
Malaise	13 (40.6)	1 (3.1)	Blood corticotrophin increased	3 (9.4)	0
Rash	12 (37.5)	2 (6.3)	Hyperthyroidism	2 (6.3)	0
Fever	11 (34.4)	1 (3.1)	ALT increased	2 (6.3)	0
Hypothyroidism	11 (34.4)	0	Mucositis oral		
AST increased	9 (28.1)	0		2 (6.3)	1
Lymphocyte count decreased	9 (28.1)	3 (9.4)	Pneumonitis	2 (6.3)	0
Diarrhea	9 (28.1)	1 (3.1)	Conclusions		
Nausea	9 (28.1)	0	Nivolumoh plue lopvotinih hov	d a managaah	
Hypoalbuminemia	9 (28.1)	2 (6.3)	 Nivolumab plus lenvatinib had a manageable safety profile in pts with advanced BTC. The efficacy in second-line treatment was limited. Biomarker studies will be analyzed in the future. 		
Weight loss	8 (25.0)	0			
Palmar-plantar erythrodysesthesia syndrome	8 (25.0)	0			
Vomiting	7 (21.9)	0			
ALT increased	6 (18.8)	1 (3.1)	Acknowledgements		
Fatigue	6 (18.8)	0	This study was funded by Ono pharmaceutical and		
Neutrophil count decreased	5 (15.6)	4 (12.5)	Correspondence: M.Ueno, makoto23u@gmail.com		





Table 3. Overall response rate subgroup analysis (n=32) Factor Subgroup ORR (%) [95% CI] PFS Median 2.5 months **MSI** status Stable 7.4 [0.9-24.3] [95% CI: 1.5-4.1] 20.0 [0.5-71.6] Unknown Gallbladder 28.6 [3.7-71.0] Primary tumor site Extrahepatic bile duct 0.0 [0.0-52.2] [0.0-28.1] Intrahepatic bile duct 0.0 [0.5-71.6] Ampullary 20.0 OS Median 6.4 months [0.2-33.9] Biliary Presence 7.1 [95% CI: 4.9-9.7] drainage [1.4-34.7] Absence 11.1 Yes [0.0-33.6] 0.0 Usage of antibiotics** 13.0 [2.8-33.6] No

Table 5. Immune-mediated adverse events (n=32)